Guobang Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Guobang Pharma has a total shareholder equity of CN¥7.8B and total debt of CN¥909.1M, which brings its debt-to-equity ratio to 11.6%. Its total assets and total liabilities are CN¥10.6B and CN¥2.8B respectively. Guobang Pharma's EBIT is CN¥811.7M making its interest coverage ratio -28. It has cash and short-term investments of CN¥2.2B.
Key information
11.6%
Debt to equity ratio
CN¥909.09m
Debt
| Interest coverage ratio | -28x |
| Cash | CN¥2.16b |
| Equity | CN¥7.85b |
| Total liabilities | CN¥2.79b |
| Total assets | CN¥10.63b |
Recent financial health updates
These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively
Jul 24
We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt
Mar 25Recent updates
Guobang Pharma Ltd. (SHSE:605507) Screens Well But There Might Be A Catch
Dec 09Calculating The Fair Value Of Guobang Pharma Ltd. (SHSE:605507)
Aug 26These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively
Jul 24Guobang Pharma Ltd. (SHSE:605507) Analysts Just Cut Their EPS Forecasts Substantially
May 21Fewer Investors Than Expected Jumping On Guobang Pharma Ltd. (SHSE:605507)
Apr 18We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt
Mar 25Financial Position Analysis
Short Term Liabilities: 605507's short term assets (CN¥5.7B) exceed its short term liabilities (CN¥2.6B).
Long Term Liabilities: 605507's short term assets (CN¥5.7B) exceed its long term liabilities (CN¥224.7M).
Debt to Equity History and Analysis
Debt Level: 605507 has more cash than its total debt.
Reducing Debt: 605507's debt to equity ratio has reduced from 34.4% to 11.6% over the past 5 years.
Debt Coverage: 605507's debt is well covered by operating cash flow (59.3%).
Interest Coverage: 605507 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 17:04 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guobang Pharma Ltd. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhu Chen | Citic Securities Co., Ltd. |
| Kai Wang | Citic Securities Co., Ltd. |
| Jiarui Lu | Guosen Securities Co., Ltd. |